# 30: Theranostics - Cutting edge Cancer Diagnosis and Treatment

Page: https://stenobird.com/podcast/tackle-talk-a-men-s-health-podcast-6805332/30-theranostics-cutting-edge-cancer-diagnosis-and-treatment
Text version: https://stenobird.com/podcast/tackle-talk-a-men-s-health-podcast-6805332/30-theranostics-cutting-edge-cancer-diagnosis-and-treatment.md
Podcast: [Tackle Talk - A Men’s Health Podcast](https://stenobird.com/podcast/tackle-talk-a-men-s-health-podcast-6805332)
Published: 2025-06-02T22:00:00+00:00
Episode link: https://www.tackletalkmenshealth.com/e/30-theranostics-cutting-edge-cancer-diagnosis-and-treatment/
Audio file: https://mcdn.podbean.com/mf/web/wzwqzscbj3itr8ft/30_Theranostics_DONE_v190wfe.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/tackle-talk-a-men-s-health-podcast-6805332/episodes/30-theranostics-cutting-edge-cancer-diagnosis-and-treatment
Duration seconds: 3620

## Resource

In our latest Tackle Talk Men’s Health episode, we explore the cutting-edge field of theranostics - also known as Targeted Radionuclide Therapy with Professor Nat Lenzo, a leader in nuclear medicine. Learn how this innovative approach is reshaping the treatment of prostate cancer and other cancers, and how Australia is leading the world in developing these innovative new therapies.

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/tackle-talk-a-men-s-health-podcast-6805332/episodes/30-theranostics-cutting-edge-cancer-diagnosis-and-treatment/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/tackle-talk-a-men-s-health-podcast-6805332/30-theranostics-cutting-edge-cancer-diagnosis-and-treatment.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.